Preclinical imaging generates enormous volumes of biological data, but images alone do not answer scientific questions. Meaningful insights depend on rigorous image analysis workflows that transform raw imaging signals into accurate, reproducible quantitative endpoints capable of supporting critical research and regulatory decisions.
This webinar explores the scientific principles behind quantitative preclinical image analysis, from segmentation and image quantification to biodistribution, dosimetry and advanced modeling. Attendees will gain practical insight into how standardized analytical workflows improve confidence in imaging biomarkers, reduce variability and strengthen translational decision-making across drug development programs.
Special emphasis will be placed on dosimetry, where quantitative image analysis directly informs human dose estimation through biodistribution modeling, time-activity curve generation and OLINDA-based calculations. Using examples from oncology and radioligand therapy research, attendees will learn why analytical rigor is essential for producing reliable, defensible results.
Register for this webinar to discover how robust image analysis transforms preclinical imaging data into actionable evidence that accelerates translational research and supports confident development decisions.
Speaker
Keryn Gresco, MS, Director, Image Analysis and Software Platforms, Perceptive Discovery
Keryn Gresco is a Scientist and Team Leader with more than a decade of experience developing quantitative image analysis workflows for preclinical and translational research. She specializes in image analysis across oncology, radioligand therapy, neurology and systemic diseases, with expertise spanning segmentation, quantitative imaging, dosimetry and software platform development.
As Director of Image Analysis and Software Platforms at Perceptive Discovery, Keryn leads a multidisciplinary team of Scientists, Engineers and Mathematicians responsible for designing and executing image analysis workflows that support studies from early discovery through IND-enabling research. Her team develops standardized analytical methods that transform complex imaging datasets into robust, reproducible endpoints used to inform critical drug development decisions.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Translational Scientists
- Preclinical Imaging Scientists
- Radiopharmaceutical and Radioligand Therapy Researchers
- Oncology Drug Development teams
- Image Analysis and Quantitative Imaging Specialists
- Pharmacology and Biodistribution Scientists
- Preclinical Research Directors and Scientific leaders
- Biotech and pharmaceutical professionals utilizing PET, SPECT, CT, MRI or multimodal imaging
- Researchers seeking to improve the reproducibility and translational value of imaging data
What You Will Learn
Attendees will:
- Understand how quantitative image analysis converts raw imaging data into meaningful biological endpoints
- Compare manual, semi-automated and AI-assisted segmentation approaches and understand when each is most appropriate
- Learn how quantitative metrics such as %ID/g, SUV and concentration measurements are derived and applied across different study types
- Explore the complete analytical workflow behind preclinical dosimetry, from biodistribution data through human dose estimation
- Understand how quality control at every stage improves the reliability and reproducibility of imaging results
- Discover how advanced analyses, including MR modeling, biodistribution, pharmacokinetics and in vitro binding studies build upon standardized quantitative workflows
- Gain practical insight into analytical strategies that strengthen translational confidence and support regulatory decision-making
Xtalks Partner
Perceptive Discovery
Perceptive Discovery bridges the gap between preclinical insights and early clinical success, providing the expertise and high-quality data needed to advance innovation with confidence. With deep expertise in advanced imaging, radiochemistry, and translational science, we specialize in supporting drug development programs across CNS, oncology, and radioligand therapy. Our integrated approach combines rigorous scientific analysis, state-of-the-art imaging platforms, and multidisciplinary expertise to deliver data that drives smarter decisions, reduces risk, and accelerates timelines from preclinical to first-in-human studies.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account